Vir Biotechnology to Unveil Long-Term Hepatitis Delta Trial Data at EASL 2026
Event summary
- Vir Biotechnology will present complete Week 96 data from the Phase 2 SOLSTICE trial for hepatitis delta at EASL Congress 2026 in Barcelona.
- The trial evaluates the combination of tobevibart and elebsiran, with results to be shared in both oral and poster presentations.
- Chronic hepatitis delta (CHD) is the most severe form of chronic viral hepatitis, with no approved treatments in the U.S. and limited options globally.
- Tobevibart and elebsiran are investigational agents designed to disrupt the HDV life cycle at multiple points.
The big picture
Vir Biotechnology's presentation of long-term data from the SOLSTICE trial comes at a critical juncture for hepatitis delta treatment, an area with significant unmet medical needs. The combination of tobevibart and elebsiran targets a dual mechanism of action, addressing both viral entry and sustained presence of hepatitis B surface antigen. Success in this trial could position Vir as a leader in a niche but high-impact therapeutic area, potentially attracting partnerships or acquisition interest.
What we're watching
- Regulatory Pathway
- Whether the Week 96 data will support regulatory filings and accelerate the approval process for the combination therapy.
- Clinical Efficacy
- The impact of BMI on ALT normalization and the long-term virologic control achieved with the combination treatment.
- Market Positioning
- How Vir Biotechnology positions this data against competitors in the hepatitis delta space and potential partnerships for global expansion.